Compare THG & IRTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | THG | IRTC |
|---|---|---|
| Founded | 1852 | 2006 |
| Country | United States | United States |
| Employees | 4900 | N/A |
| Industry | Property-Casualty Insurers | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.6B | 5.8B |
| IPO Year | 1995 | 2016 |
| Metric | THG | IRTC |
|---|---|---|
| Price | $186.42 | $176.37 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 14 |
| Target Price | $196.67 | ★ $204.64 |
| AVG Volume (30 Days) | 260.5K | ★ 423.3K |
| Earning Date | 02-03-2026 | 10-30-2025 |
| Dividend Yield | ★ 2.04% | N/A |
| EPS Growth | ★ 73.14 | N/A |
| EPS | ★ 17.31 | N/A |
| Revenue | ★ $6,506,900,000.00 | $702,573,000.00 |
| Revenue This Year | $4.23 | $27.20 |
| Revenue Next Year | $5.18 | $16.91 |
| P/E Ratio | $10.77 | ★ N/A |
| Revenue Growth | 5.26 | ★ 25.45 |
| 52 Week Low | $145.17 | $86.19 |
| 52 Week High | $188.18 | $212.00 |
| Indicator | THG | IRTC |
|---|---|---|
| Relative Strength Index (RSI) | 60.47 | 51.01 |
| Support Level | $182.70 | $166.49 |
| Resistance Level | $187.37 | $182.38 |
| Average True Range (ATR) | 3.20 | 5.66 |
| MACD | 0.16 | 0.56 |
| Stochastic Oscillator | 84.42 | 58.59 |
The Hanover Insurance Group Inc is a holding company whose primary business is offering property and casualty insurance products and services. The company markets itself through independent agents and brokers in the United States while conducting business internationally through a wholly owned subsidiary, Chaucer Holdings Limited, domiciled in the United Kingdom. The company conducts business operations through four operating segments: Core Commercial, Specialty, Personal Lines, and Other. The company operates an investment portfolio that is exposed to fixed-income securities.
iRhythm Technologies Inc is a digital healthcare company that creates trusted solutions that detect, predict, and prevent disease. Its principal business is the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services that it believes allow clinicians to diagnose certain arrhythmias quicker and with greater efficiency than other services that rely on traditional technology. Each Zio System combines an FDA-cleared and CE-marked, wire-free, patch-based, 14-day wearable biosensor that continuously records electrocardiogram (ECG) data with a proprietary, FDA-cleared, CE-marked cloud-based data analytic software to help physicians monitor patients and diagnose arrhythmias.